Temporal lobe epilepsy (TLE) is one of the most common types of epilepsy worldwide. Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. Neuroscientist have recently identified and developed a new drug candidate that has potential for effectively treating TLE by suppressing neuroinflammation.